USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Sumitomo Pharma Co., Ltd.

USPTO PatentsView assignee record - 63 granted patents across 20 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

23.1

Avg claims per patent

5-year grant velocity

The verdict

According to USPTO PatentsView, Sumitomo ranks #5,475 of 50,000 tracked US assignees by granted-patent volume, with 63 patents across 20 technology areas.

#5,475
of 50,000 US assignees by volume: Top 2%
by Innovation Score (64.0/100): 23.1
avg claims per patent

Portfolio overview

Sumitomo Pharma Co., Ltd. has been granted 63 US utility patents between 2022 and 2025, placing Sumitomo Pharma Co., Ltd. at #5,475 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Sumitomo Pharma Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Sumitomo sits between Siemens Healthcare Diagnostics Products Gmbh (63 patents, rank #5,471) and Therma-stor Llc (63 patents, rank #5,479) - the closest US assignees by grant volume. The composite Innovation Score of 64.0/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2022 through 2025, with 63 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Sumitomo Pharma Co., Ltd.'s 23.1 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 20 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Siemens Healthcar…

63
Silanna UV Pte

63
Simplify Medical…

63
Skyhook Wireless

63
Suncor Energy

63
Taser Internation…

63
Tempus LABS

63
Therma-stor

63
Sumitomo Pharma ◀

63

What this shows Sumitomo holds 63 patents at rank #5,475, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sumitomo

By rank, the assignees closest to #5,475 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Sumitomo's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sumitomo, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (64 here).

Furuno Electric Company Limited 64 Luxshare Precision Industry Company Limited 64 Maxar Space Llc 64 Citibank, N.a. 64

Similar claim depth

Nearest assignees by average claims per patent (23.1 here).

Qumulo, Inc. 23.1 avg Pensando Systems Inc. 23.1 avg Elta Systems Ltd. 23.1 avg Cytokinetics, Inc. 23.1 avg

Sumitomo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

64 Top 2% higher than 98% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Sumitomo Pharma Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	11	17.5%
2023	19	30.2%
2024	19	30.2%
2025partial year	14	22.2%

Which technologies does Sumitomo Pharma Co., Ltd. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 52

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 50

C07D - HETEROCYCLIC COMPOUNDS 27

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 13

C07K - PEPTIDES 12

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 10

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 9

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 6

G06F - ELECTRIC DIGITAL DATA PROCESSING 3

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 3

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 3

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 2

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 2

G09B - EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS 2

G06T - IMAGE DATA PROCESSING OR GENERATION, IN GENERAL 2

Top 15 of 20 technology areas

Grant record at a glance

Portfolio Volume 63 grants

CPC subclasses 20

Avg. claims / grant 23.1

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#5,475

of 50,000 tracked assignees

Innovation Score

64.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Sumitomo Pharma Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sumitomo Pharma Co., Ltd. ranks #5,475 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sumitomo Pharma Co., Ltd. hold?

Sumitomo Pharma Co., Ltd. holds 63 US utility patents granted between 2022 and 2025, spanning 20 technology areas.

What is Sumitomo Pharma Co., Ltd.'s Innovation Score?

Sumitomo Pharma Co., Ltd. has an Innovation Score of 64.0 out of 100 (top 2% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sumitomo Pharma Co., Ltd. focus on?

Sumitomo Pharma Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 52 patents. Grants appear in 20 CPC subclasses total.

Is Sumitomo Pharma Co., Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Sumitomo Pharma Co., Ltd..

What does claim depth mean for Sumitomo Pharma Co., Ltd.'s patents?

Sumitomo Pharma Co., Ltd.'s patents average 23.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sumitomo Pharma Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Sumitomo's 63 grants land it in the top 2% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Sumitomo ranks #5,475 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.